Fig. 3
From: Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Identification of TMZ Sensitive (S) and Non-Sensitive (NS) individuals. A Workflow of Glioma orthotopic xenograft model construction and TMZ treatment. B Effect of glioma development and TMZ administration on mice body weight. C TMZ efficacy evaluated by Relative Total Flux (Flux day 14/Flux day 7) and tumor inhibition rate on TMZ S (n = 13) and NS (n = 14) mice, respectively. (D) Representative photos, BLI images, HE staining and immunohistochemistry (Ki67) of S and NS mice